BACKGROUND: Mycosis fungoides and Sézary syndrome are a class of lymphomas of skin-trafficking T cells, and they are the most common forms of cutaneous T-cell lymphoma (CTCL). Mycosis fungoides and Sézary syndrome are chronic, frequently incurable diseases with limited therapeutic options. PF-3512676 (formerly CPG 7909) is a Toll-like receptor 9 agonist that is being investigated for treatment of patients with advanced cancer. OBJECTIVE: This study was conducted to determine the safety and tolerability of single-agent PF-3512676 in patients with CTCL. METHODS: In this phase I dose-escalation study, patients (N = 28) with treatment-refractory, stage IB to IVA CTCL were enrolled in 6 sequential cohorts and treated with PF-3512676 (0.08, 0.16, 0.24, 0.28, 0.32, or 0.36 mg/kg) administered as 24 weekly subcutaneous injections. Primary end points were safety and tolerability. RESULTS: Common adverse events (fatigue, rigors, injection-site reactions, myalgia, lymphopenia, leukopenia, neutropenia, and pyrexia) were mostly grade 1 or 2, and no patient developed specific symptoms associated with autoimmune disease. Clinical response rate to PF-3512676, as determined by both Composite Assessment of Index Lesion Severity and Physician Global Assessment, was 32% (3 complete clinical responses, 6 partial responses); the majority of responses (7/9; 78%) were ongoing at the end of study. LIMITATIONS: This trial was not designed to rigorously assess efficacy. CONCLUSION: Single-agent PF-3512676 was well tolerated and demonstrated antitumor activity in patients with refractory CTCL.
BACKGROUND:Mycosis fungoides and Sézary syndrome are a class of lymphomas of skin-trafficking T cells, and they are the most common forms of cutaneous T-cell lymphoma (CTCL). Mycosis fungoides and Sézary syndrome are chronic, frequently incurable diseases with limited therapeutic options. PF-3512676 (formerly CPG 7909) is a Toll-like receptor 9 agonist that is being investigated for treatment of patients with advanced cancer. OBJECTIVE: This study was conducted to determine the safety and tolerability of single-agent PF-3512676 in patients with CTCL. METHODS: In this phase I dose-escalation study, patients (N = 28) with treatment-refractory, stage IB to IVACTCL were enrolled in 6 sequential cohorts and treated with PF-3512676 (0.08, 0.16, 0.24, 0.28, 0.32, or 0.36 mg/kg) administered as 24 weekly subcutaneous injections. Primary end points were safety and tolerability. RESULTS: Common adverse events (fatigue, rigors, injection-site reactions, myalgia, lymphopenia, leukopenia, neutropenia, and pyrexia) were mostly grade 1 or 2, and no patient developed specific symptoms associated with autoimmune disease. Clinical response rate to PF-3512676, as determined by both Composite Assessment of Index Lesion Severity and Physician Global Assessment, was 32% (3 complete clinical responses, 6 partial responses); the majority of responses (7/9; 78%) were ongoing at the end of study. LIMITATIONS: This trial was not designed to rigorously assess efficacy. CONCLUSION: Single-agent PF-3512676 was well tolerated and demonstrated antitumor activity in patients with refractory CTCL.
Authors: Clive S Zent; Brian J Smith; Zuhair K Ballas; James E Wooldridge; Brian K Link; Timothy G Call; Tait D Shanafelt; Deborah A Bowen; Neil E Kay; Thomas E Witzig; George J Weiner Journal: Leuk Lymphoma Date: 2011-09-19
Authors: Maria Wysocka; Noor Dawany; Bernice Benoit; Andrew V Kossenkov; Andrea B Troxel; Joel M Gelfand; Michael Kelly Sell; Louise C Showe; Alain H Rook Journal: Leuk Lymphoma Date: 2011-10
Authors: Jamie K Hu; Hee-Won Suh; Munibah Qureshi; Julia M Lewis; Sharon Yaqoob; Zoe M Moscato; Sofia Griff; Alison K Lee; Emily S Yin; W Mark Saltzman; Michael Girardi Journal: Proc Natl Acad Sci U S A Date: 2021-02-16 Impact factor: 11.205
Authors: Youn H Kim; Dita Gratzinger; Cameron Harrison; Joshua D Brody; Debra K Czerwinski; Weiyun Z Ai; Anjali Morales; Farah Abdulla; Leon Xing; Daniel Navi; Robert J Tibshirani; Ranjana H Advani; Bharathi Lingala; Sumit Shah; Richard T Hoppe; Ronald Levy Journal: Blood Date: 2011-11-01 Impact factor: 22.113
Authors: Chandra P Belani; John J Nemunaitis; Abraham Chachoua; Peter D Eisenberg; Luiz E Raez; J Daniel Cuevas; Cecile B Mather; Rebecca J Benner; Sandra J Meech Journal: Cancer Biol Ther Date: 2013-05-10 Impact factor: 4.742
Authors: Leonie van Meer; Matthijs Moerland; Jolie Gallagher; Martijn B A van Doorn; Errol P Prens; Adam F Cohen; Robert Rissmann; Jacobus Burggraaf Journal: Br J Clin Pharmacol Date: 2016-05-31 Impact factor: 4.335